Analyst David Martin PhD of Bloom Burton maintained a Buy rating on Knight Therapeutics (KHTRF – Research Report), with a price target of ...

Analyst Jeffrey Hung of Morgan Stanley maintained a Hold rating on PTC Therapeutics (PTCT – Research Report), retaining the price target ...

Onkure Therapeutics, Inc. (OKUR) has disclosed a new risk, in the Corporate Activity and Growth category. Onkure Therapeutics ...

Cutia Therapeutics’ CEO, Ms. Zhang Lele, has further increased her stake in the company by purchasing an additional 5,000 ...

Sarepta Therapeutics is advancing SRP-9003 gene therapy for LGMD, with phase 3 study results expected in early 2025. Learn ...

During the third quarter, TG Therapeutics boosted Briumvi's market penetration, driving U.S. net revenue up by over 230% year ...

TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

Genmab reported impressive earnings with significant revenue growth driven by its key products, despite rising expenses.

TG Therapeutics Inc (NASDAQ:TGTX) reported strong third-quarter US net sales of $83.3 million, reflecting approximately 15% quarter-over-quarter growth and over 230% growth from the same quarter ...

Growth investors, on the other hand ... Silver Spring, MD-based United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH ...

Hoth Therapeutics (HOTH) announced early data from a preclinical study of its latest cancer treatment. The preliminary results demonstrate that the treatment successfully stabilizes tumor growth ...

Viridian Therapeutics VRDN has been analyzed by 12 analysts in the last three months, revealing a diverse range of ...